BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857-866. [PMID: 12873880 DOI: 10.1001/archderm.139.7.857] [Cited by in Crossref: 396] [Cited by in F6Publishing: 438] [Article Influence: 19.8] [Reference Citation Analysis]
Number Citing Articles
1 Porkert S, Valencak J. Cutaneous lymphomas—fast facts about an orphan disease—a short review. memo 2023. [DOI: 10.1007/s12254-022-00863-0] [Reference Citation Analysis]
2 Fay CJ, Awh KC, Leboeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
3 Schaefer L, Comfere N, Sokumbi O. Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review. Am J Clin Dermatol 2023. [PMID: 36627479 DOI: 10.1007/s40257-022-00749-1] [Reference Citation Analysis]
4 Glinos G, Wei G, Nosewicz J, Abdulla F, Chen PL, Chung C, Kaffenberger BH, Querfeld C, Shinohara MM, Sokol L, Zain J, Kumar A, Seminario-Vidal L. Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma. JAMA Dermatol 2023. [PMID: 36598766 DOI: 10.1001/jamadermatol.2022.5740] [Reference Citation Analysis]
5 Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
6 Segal O, Goldzweig G, Shapiro Bratt I, Baum S, Lyakhovitsky A, Barzilai A. Illness Perception Regarding Early-stage Mycosis Fungoides among Dermatologists: A Multi-centre Cross-sectional Study. Acta Derm Venereol 2022;102:adv00784. [DOI: 10.2340/actadv.v102.2046] [Reference Citation Analysis]
7 King ALO, Lee V, Mirza FN, Jairam V, Yang DX, Yu JB, Park HS, Girardi M, Wilson LD, An Y. Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis. Cureus 2022. [DOI: 10.7759/cureus.28043] [Reference Citation Analysis]
8 Hawkins N, Muszbek N, Evans R, Dequen-O'Byrne P, Jones T, McNamara L. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome. J Comp Eff Res 2022;11:805-13. [PMID: 35678206 DOI: 10.2217/cer-2022-0070] [Reference Citation Analysis]
9 Navarro Matilla B, Onteniente Gomis MDM, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, Muniesa Montserrat C, González Barca E, Morillo Andújar M, Pérez Ferriols A, Román Curto MC, Fernández de Misa Cabrera R, Hospital Gil M, Marín Niebla A, Rios Rull PJ, de la Cruz Vicente F, Izu Belloso RM, Martín García‐sancho A, Parera Amer ME, Córdoba Mascuñano R, Ramón Quiles MD, Saus Carreres A, del Campo García R, Machan S, Viguera Ester P, Blanco Garnelo J, Soler López B, Ortiz Romero PL. EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study). JEADV Clinical Practice 2022. [DOI: 10.1002/jvc2.39] [Reference Citation Analysis]
10 Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney DK. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2081322] [Reference Citation Analysis]
11 Polgárová K, Polívka J, Kodet O, Klener P, Trněný M. Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience. Front Oncol 2022;12:884091. [DOI: 10.3389/fonc.2022.884091] [Reference Citation Analysis]
12 Lenskaya V, de Moll EH, Hussein S, Phelps RG. Subtlety of Granulomatous Mycosis Fungoides: A Retrospective Case Series Study and Proposal of Helpful Multimodal Diagnostic Approach With Literature Review. Am J Dermatopathol 2022. [PMID: 35476045 DOI: 10.1097/DAD.0000000000002181] [Reference Citation Analysis]
13 Goyal A, Nardi V. Gamma/Delta (γδ) T Cells: The Role of the T-Cell Receptor in Diagnosis and Prognosis of Hematologic Malignancies. Am J Dermatopathol 2022;44:237-48. [PMID: 35287137 DOI: 10.1097/DAD.0000000000002041] [Reference Citation Analysis]
14 Franceschi J, Ehret M, Visseaux L, Durlach A, Barbe C, Durot É, Grange F. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas. Acta Derm Venereol 2022;102:adv00676. [DOI: 10.2340/actadv.v102.1087] [Reference Citation Analysis]
15 Salant JA, Khan N, Nelson JE, Norton-Westbrook M, Desai AV. Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. J Palliat Med 2021. [PMID: 34978848 DOI: 10.1089/jpm.2021.0610] [Reference Citation Analysis]
16 Chan WH, Lewis DJ, Duvic M, Feldman SR. Strategies to Optimize Adherence in Patients with Mycosis Fungoides. Cells 2021;11:113. [PMID: 35011675 DOI: 10.3390/cells11010113] [Reference Citation Analysis]
17 Podkonjak T, Cranmer H, Scarisbrick J, McCarthy G, Lilley C, Cheng LI. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. J Comp Eff Res 2021. [PMID: 34879742 DOI: 10.2217/cer-2021-0201] [Reference Citation Analysis]
18 Jiang TT, Kruglov O, Lin GHY, Minic A, Jordan K, Uger RA, Wong M, Shou Y, Akilov OE. Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides. Cancers (Basel) 2021;13:5982. [PMID: 34885092 DOI: 10.3390/cancers13235982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, Johns C, McCann S, Lin GHY, Petrova PS, Uger RA, Molloy N, Shou Y, Akilov OE. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol 2021;8:e808-17. [PMID: 34627593 DOI: 10.1016/S2352-3026(21)00271-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides und Sézary-Syndrom. J Dtsch Dermatol Ges 2021;19:1307-35. [PMID: 34541808 DOI: 10.1111/ddg.14610_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides and Sézary syndrome. J Dtsch Dermatol Ges 2021;19:1307-34. [PMID: 34541796 DOI: 10.1111/ddg.14610] [Reference Citation Analysis]
23 Kruglov O, Johnson LDS, Minic A, Jordan K, Uger RA, Wong M, Sievers EL, Shou Y, Akilov OE. The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer Immunol Immunother 2021. [PMID: 34519839 DOI: 10.1007/s00262-021-03051-x] [Reference Citation Analysis]
24 Roccuzzo G, Giordano S, Fava P, Pileri A, Guglielmo A, Tonella L, Sanlorenzo M, Ribero S, Fierro MT, Quaglino P. Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Front Oncol 2021;11:733770. [PMID: 34485162 DOI: 10.3389/fonc.2021.733770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Jung JM, Lim DJ, Won CH, Chang SE, Lee MW, Lee WJ. Mycosis Fungoides in Children and Adolescents: A Systematic Review. JAMA Dermatol 2021;157:431-8. [PMID: 33656521 DOI: 10.1001/jamadermatol.2021.0083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Charli-Joseph Y, Kashani-Sabet M, McCalmont TH, Kornak J, Allen I, Ai WZ, LeBoit PE, Pincus LB. Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort. JAMA Dermatol 2021;157:157-65. [PMID: 33295938 DOI: 10.1001/jamadermatol.2020.4372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Kaemmerer T, Stadler PC, Helene Frommherz L, Guertler A, Einar French L, Reinholz M. Alitretinoin in the treatment of cutaneous T-cell lymphoma. Cancer Med 2021;10:7071-8. [PMID: 34435474 DOI: 10.1002/cam4.4237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Miyashiro D, Sanches JA. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort. Int J Dermatol 2021. [PMID: 34435672 DOI: 10.1111/ijd.15865] [Reference Citation Analysis]
29 Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Cutaneous T cell lymphoma. Nat Rev Dis Primers 2021;7:61. [PMID: 34446710 DOI: 10.1038/s41572-021-00296-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
30 Wennberg E, Richards PQ, Bain PA, Huang V, Sullivan SD, Maverakis EM, Molina GE, Wu PA. Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review. JAAD Int 2021;3:26-41. [PMID: 34409369 DOI: 10.1016/j.jdin.2021.01.002] [Reference Citation Analysis]
31 Johnson WT, Kartan S, Sokol K, Nikbakht N, Porcu P. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial. Leuk Lymphoma 2021;62:1877-83. [PMID: 33618592 DOI: 10.1080/10428194.2021.1888376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Weeks S, Harris R, Karimi M. Targeting ITK signaling for T cell-mediated diseases. iScience 2021;24:102842. [PMID: 34368657 DOI: 10.1016/j.isci.2021.102842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Suh KS, Jang MS, Jung JH, Kwon DI, Seong SH, Lee KH, Park JB. Clinical characteristics and long-term outcome of 223 patients with mycosis fungoides at a single tertiary center in Korea: A 29-year review. J Am Acad Dermatol 2021:S0190-9622(21)02005-3. [PMID: 34197872 DOI: 10.1016/j.jaad.2021.06.860] [Reference Citation Analysis]
34 Pruksaeakanan C, Teyateeti P, Patthamalai P, Thumrongtharadol J, Chairatchaneeboon M. Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study. Biomed Res Int 2021;2021:4057661. [PMID: 34235215 DOI: 10.1155/2021/4057661] [Reference Citation Analysis]
35 Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. Dermatol Ther (Heidelb) 2021;11:1085-106. [PMID: 34021485 DOI: 10.1007/s13555-021-00539-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
36 Moon IJ, Lee KH, Choi JW, Lee WJ, Won CH, Chang S, Choi JH, Lee MW. Clinical characteristics and long-term outcomes of 97 Korean patients with mycosis fungoides. Int J Dermatol 2021. [PMID: 33991105 DOI: 10.1111/ijd.15561] [Reference Citation Analysis]
37 Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, Hoppe RT, Kim YH. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv 2020;4:4474-82. [PMID: 32941647 DOI: 10.1182/bloodadvances.2020001627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Kruglov O, Wu X, Hwang ST, Akilov OE. The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. Blood Adv 2020;4:4788-97. [PMID: 33017467 DOI: 10.1182/bloodadvances.2020002049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hoffmann JC, Atwater SK, Hong E, Kumar J, Khodadoust M, Kim Y, Ohgami RS. A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. Am J Dermatopathol 2020;42:389-96. [PMID: 32433315 DOI: 10.1097/DAD.0000000000001637] [Reference Citation Analysis]
40 Jung JM, Yoo H, Lim DJ, Won CH, Chang SE, Lee MW, Lee WJ. Clinicoprognostic implications of head and neck involvement by mycosis fungoides: A retrospective cohort study. J Am Acad Dermatol 2021:S0190-9622(21)00609-5. [PMID: 33771590 DOI: 10.1016/j.jaad.2021.03.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Bessell E, Dalton M, Parry JD. Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for >15 Years with Localised Electron Beam Therapy. Case Rep Dermatol Med 2021;2021:5541246. [PMID: 33791133 DOI: 10.1155/2021/5541246] [Reference Citation Analysis]
42 Karagianni F, Piperi C, Mpakou V, Spathis A, Foukas PG, Dalamaga M, Pappa V, Papadavid E. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. PLoS One 2021;16:e0248298. [PMID: 33705488 DOI: 10.1371/journal.pone.0248298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Vermeer MH, Nicolay JP, Scarisbrick JJ, Zinzani PL. The importance of assessing blood tumour burden in cutaneous T-cell lymphoma. Br J Dermatol 2021;185:19-25. [PMID: 33155285 DOI: 10.1111/bjd.19669] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
44 Severson KJ, Cumsky HJL, Brumfiel CM, Janeczek MC, Ginos BF, Kosiorek HE, Besch-Stokes J, Patel MH, Rule WG, DiCaudo DJ, Rosenthal AC, Pittelkow MR, Mangold AR. Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. J Am Acad Dermatol 2021:S0190-9622(21)00204-8. [PMID: 33493572 DOI: 10.1016/j.jaad.2021.01.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Mateeva V, Patsatsi A. Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clin Dermatol 2021;39:64-75. [PMID: 33972055 DOI: 10.1016/j.clindermatol.2020.12.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Hoffmann JC, Maeda LS, Ohgami RS. Indolent and Aggressive Mature T-Cell and Natural Killer–Cell Lymphomas. Atlas of Diagnostic Hematology 2021. [DOI: 10.1016/b978-0-323-56738-1.00013-0] [Reference Citation Analysis]
47 Bahalı AG, Su O, Cengiz FP, Emiroğlu N, Ozkaya DB, Onsun N. Prognostic factors of patients with mycosis fungoides. Postepy Dermatol Alergol 2020;37:796-9. [PMID: 33240023 DOI: 10.5114/ada.2020.100491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, Fujita H, Izutsu K, Okuma K, Kawai K, Koga H, Sugaya M. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 2021;48:e49-71. [PMID: 33245165 DOI: 10.1111/1346-8138.15707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
49 Bienz MN, Petrogiannis-Haliotis T, Pehr K, Benlimame N, Mai S, Knecht H. Three-Dimensional Telomeric Fingerprint of Mycosis Fungoides and/or Sézary Syndrome: A Pilot Study. J Invest Dermatol 2021;141:1598-1601.e4. [PMID: 33212153 DOI: 10.1016/j.jid.2020.09.032] [Reference Citation Analysis]
50 Attia SJ. Classification of Optical Images of Cervical Lymph Node Cells. IOP Conf Ser : Mater Sci Eng 2020;928:072049. [DOI: 10.1088/1757-899x/928/7/072049] [Reference Citation Analysis]
51 Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
52 Bolcato V, Barruscotti S, DE Silvestri A, Tomasini CF, Brazzelli V. Sézary Syndrome: a clinico-pathological study of 9 cases. Ital J Dermatol Venerol 2021;156:73-83. [PMID: 33084262 DOI: 10.23736/S2784-8671.19.06403-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Brouwer IJ, Out-Luiting JJ, Vermeer MH, Tensen CP. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. Biochem Biophys Rep 2020;24:100832. [PMID: 33102814 DOI: 10.1016/j.bbrep.2020.100832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
54 Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:97-105. [PMID: 33158772 DOI: 10.1016/j.clml.2020.09.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
55 Blackmon AL, Pinter-Brown L. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection. Drug Des Devel Ther 2020;14:3747-54. [PMID: 32982179 DOI: 10.2147/DDDT.S185896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ; Cutaneous Lymphoma International Consortium (CLIC) institutions. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol 2021;184:524-31. [PMID: 32574377 DOI: 10.1111/bjd.19303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Lee C, Peddi S, Anderson C, Su H, Cui H, Epstein AL, MacKay JA. Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma. Biomaterials 2020;262:120338. [PMID: 32916604 DOI: 10.1016/j.biomaterials.2020.120338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
59 Williams K, Gibson A, McNamara L, Jones T, Lloyd AJ. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL). J Med Econ 2020;23:1142-50. [PMID: 32644862 DOI: 10.1080/13696998.2020.1793764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Johnson LDS, Banerjee S, Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Querfeld C, Chen R, Okada C, Sawas A, O'Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov OE. Targeting CD47 in Sézary syndrome with SIRPαFc. Blood Adv 2019;3:1145-53. [PMID: 30962222 DOI: 10.1182/bloodadvances.2018030577] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 17.0] [Reference Citation Analysis]
61 Pratt M, Glassman SJ. Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: A possible new regimen for the treatment of advanced cutaneous T-cell lymphoma. JAAD Case Rep 2020;6:581-3. [PMID: 32685643 DOI: 10.1016/j.jdcr.2020.05.013] [Reference Citation Analysis]
62 Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 2021;100:183-91. [PMID: 32667737 DOI: 10.1002/cyto.b.21933] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
63 . Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020;61:2955-61. [DOI: 10.1080/10428194.2020.1790555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
65 Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
66 Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol 2021;141:364-73. [PMID: 32603749 DOI: 10.1016/j.jid.2020.05.110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
67 Pulitzer MP, Horna P, Almeida J. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. Cytometry B Clin Cytom 2021;100:132-8. [PMID: 32516521 DOI: 10.1002/cyto.b.21888] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
68 Georgakopoulos I, Papadavid E, Platoni K, Kougioumtzopoulou A, Patatoukas G, Kypraiou E, Nikolaou V, Efstathopoulos E, Kelekis N, Kouloulias V. Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas. Dermatol Ther 2020;33:e13478. [PMID: 32391976 DOI: 10.1111/dth.13478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Williams KA, Kwatra SG. Emerging Research in Chronic Pruritus: From Bedside to Bench and Back Again. Medicines (Basel) 2020;7:E24. [PMID: 32365507 DOI: 10.3390/medicines7050024] [Reference Citation Analysis]
70 Wang Y, Niu Z, Liu J, Zhu Q, Liu Z, Liu Y, Jin H. Value of High-Frequency Ultrasound in Accurate Staging of Mycosis Fungoides/Sézary Syndrome. J Ultrasound Med 2020;39:1927-37. [PMID: 32319698 DOI: 10.1002/jum.15297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
71 Daniels J, Doukas PG, Escala MEM, Ringbloom KG, Shih DJH, Yang J, Tegtmeyer K, Park J, Thomas JJ, Selli ME, Altunbulakli C, Gowthaman R, Mo SH, Jothishankar B, Pease DR, Pro B, Abdulla FR, Shea C, Sahni N, Gru AA, Pierce BG, Louissaint A Jr, Guitart J, Choi J. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat Commun 2020;11:1806. [PMID: 32286303 DOI: 10.1038/s41467-020-15572-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
72 Hirji SH, Maeng MM, Tran AQ, Lin WW, Glass LRD. Cutaneous T-cell lymphoma of the eyelid masquerading as dermatitis. Orbit 2021;40:75-8. [PMID: 32160808 DOI: 10.1080/01676830.2020.1739080] [Reference Citation Analysis]
73 Craig FE. It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides. Cytometry B Clin Cytom 2021;100:125-8. [PMID: 32083391 DOI: 10.1002/cyto.b.21872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
74 Ortiz-Romero PL, Servitje O, Estrach MT, Izu-Belloso RM, Fernández-de-Misa R, Gallardo F, López-Martínez N, Pérez-Mitru A. Cost of early-stage mycosis fungoides treatments in Spain. Clinicoecon Outcomes Res 2020;12:91-105. [PMID: 32104021 DOI: 10.2147/CEOR.S233376] [Reference Citation Analysis]
75 Mourad A, Gniadecki R. Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology 2020;140:495-497.e5. [DOI: 10.1016/j.jid.2019.07.712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
76 Voorhees TJ, Bowers EV, Kelsey CR, Park Y, Beaven AW. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome. Novel Therapeutics for Rare Lymphomas 2020. [DOI: 10.1007/978-3-030-25610-4_14] [Reference Citation Analysis]
77 Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation 2020;26:76-82. [DOI: 10.1016/j.bbmt.2019.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
78 Margaritescu I, Chirita A, Addis K, Dinehart MS, Carlock S, Abate MS, Smoller BR. Cutaneous Lymphomas and Lymphocytic Infiltrates. Atlas of Dermatology, Dermatopathology and Venereology 2020. [DOI: 10.1007/978-3-319-45134-3_83-1] [Reference Citation Analysis]
79 Querfeld C, Rosen ST, Duvic M. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00104-3] [Reference Citation Analysis]
80 Kaul S, Belzberg M, Hughes JM, Mahadevan V, Khanna R, Bakhshi PR, Hong MS, Williams KA, Grossberg AL, Kwatra SG, Sweren RJ. Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center. Medicines (Basel) 2019;7:E1. [PMID: 31888015 DOI: 10.3390/medicines7010001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Wang X, Xue G, Pan Z. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK). Eur J Med Chem 2020;187:111918. [PMID: 31830635 DOI: 10.1016/j.ejmech.2019.111918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
82 Seffens A, Herrera A, Tegla C, Buus TB, Hymes KB, Ødum N, Geskin LJ, Koralov SB. STAT3 Dysregulation in Mature T and NK Cell Lymphomas. Cancers (Basel) 2019;11:E1711. [PMID: 31684088 DOI: 10.3390/cancers11111711] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
83 O'Malley JT, de Masson A, Lowry EL, Giobbie-Hurder A, LeBoeuf NR, Larocca C, Gehad A, Seger E, Teague JE, Fisher DC, Kupper TS, Devlin PM, Clark RA. Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 2020;26:408-18. [PMID: 31636100 DOI: 10.1158/1078-0432.CCR-18-4147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
84 Wu JH, Cohen BA, Sweren RJ. Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management. Pediatr Dermatol 2019;37:18-28. [DOI: 10.1111/pde.14026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
85 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
86 Heyman B, Kelsey CR, Beaven A. Durable Control of Mycosis Fungoides after Sepsis: "Coley's Toxin?" Case Report and Review of the Literature. Case Rep Hematol 2019;2019:1507014. [PMID: 31467737 DOI: 10.1155/2019/1507014] [Reference Citation Analysis]
87 Gao C, Mccormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 2019;134:1346-50. [DOI: 10.1182/blood.2019000765] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
88 Specht L, Skov L. Cutaneous Lymphomas. Clin Oncol (R Coll Radiol) 2019;31:797-807. [PMID: 31405542 DOI: 10.1016/j.clon.2019.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Khan S, Sawas A. Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. Front Oncol 2019;9:645. [PMID: 31417860 DOI: 10.3389/fonc.2019.00645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
90 Molloy K, Jonak C, Woei‐a‐jin F, Guenova E, Busschots A, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, Cowan R, Papadavid E, Beylot‐barry M, Berti E, Alberti Violetti S, Estrach T, Matin R, Akilov O, Vakeva L, Prince M, Bates A, Bayne M, Wachsmuch R, Wehkamp U, Marschalko M, Servitje O, Turner D, Weatherhead S, Wobser M, Sanches J, Mckay P, Klemke D, Peng C, Howles A, Yoo J, Evison F, Scarisbrick J. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( PROCLIPI ) study. Br J Dermatol 2020;182:770-9. [DOI: 10.1111/bjd.18089] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
91 Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blümel E, Rittig AH, Celis P, Herpers B, Becker JC, Stausbøl-Grøn B, Wasik MA, Gluud M, Fredholm S, Buus TB, Johansen C, Nastasi C, Peiffer L, Kubat L, Bzorek M, Eriksen JO, Krejsgaard T, Bonefeld CM, Geisler C, Mustelin T, Langhoff E, Givskov M, Woetmann A, Kilian M, Litman T, Iversen L, Odum N. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 2019;134:1072-83. [PMID: 31331920 DOI: 10.1182/blood.2018888107] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
92 Novelli S, Monter A, Pilar García-Muret M, Martino R, Briones J, Sierra J. Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. Int J Hematol 2019;110:406-10. [PMID: 31317515 DOI: 10.1007/s12185-019-02707-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol 2018;42:726-34. [PMID: 29543675 DOI: 10.1097/PAS.0000000000001041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
94 Larocca CA, LeBoeuf NR. Overview of Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am 2019;33:669-86. [PMID: 31229162 DOI: 10.1016/j.hoc.2019.04.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
95 Mahévas T, Ram‐wolff C, Battistella M, Pennamen M, Rivet J, Brice P, Bagot M. Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission. Br J Dermatol 2019;180:1517-20. [DOI: 10.1111/bjd.17254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
96 Pavlotsky F, Dawood M, Barzilai A. Potential of narrow-band ultraviolet B to induce sustained durable complete remission off-therapy in patients with stage I mycosis fungoides. Journal of the American Academy of Dermatology 2019;80:1550-5. [DOI: 10.1016/j.jaad.2018.05.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
97 Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget 2019;10:3104-13. [PMID: 31139323 DOI: 10.18632/oncotarget.5742] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
98 Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, Glassman SJ, Sasseville D, Litvinov IV. Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). Front Oncol 2019;9:300. [PMID: 31106143 DOI: 10.3389/fonc.2019.00300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
99 Ito A, Sugita K, Ikeda A, Yamamoto O. CD4/CD8 Double-negative Mycosis Fungoides: A Case Report and Literature Review. Yonago Acta Med 2019;62:153-8. [PMID: 30962758 [PMID: 30962758 DOI: 10.33160/yam.2019.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
100 Ling YL, Huang X, Mitri G, Lovelace B, Pham A, Knobler R, Li X, Gao X. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. J Dermatolog Treat 2020;31:91-8. [PMID: 30892982 DOI: 10.1080/09546634.2019.1587144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
101 Lim HLJ, Tan EST, Tee SI, Ho ZY, Boey JJJ, Tan WP, Tang MBY, Shen L, Chan YH, Tan SH. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review. J Eur Acad Dermatol Venereol 2019;33:1513-21. [PMID: 30801779 DOI: 10.1111/jdv.15526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
102 Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, Dommann-Scherrer C, Rütti M, Müller AM, Nair G, Kamarachev J, Kerl K, Beer M, Messerli M, Frauenknecht K, Haralambieva E, Hoetzenecker W, French LE, Guenova E. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol 2019;181:1296-302. [PMID: 30565216 DOI: 10.1111/bjd.17535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
103 An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 2019;131:88-92. [PMID: 30773193 DOI: 10.1016/j.radonc.2018.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Jaque A, Mereniuk A, Walsh S, Shear NH, Sade S, Zagorski B, Alhusayen R. Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients. Int J Dermatol 2019;58:933-9. [DOI: 10.1111/ijd.14391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
105 Xia FD, Ferket BS, Huang V, Stern RS, Wu PA. Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States. Journal of the American Academy of Dermatology 2019;80:485-492.e4. [DOI: 10.1016/j.jaad.2018.07.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
106 Vieyra-Garcia P, Crouch JD, O'Malley JT, Seger EW, Yang CH, Teague JE, Vromans AM, Gehad A, Win TS, Yu Z, Lowry EL, Na JI, Rook AH, Wolf P, Clark RA. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. JCI Insight 2019;4:124233. [PMID: 30626755 DOI: 10.1172/jci.insight.124233] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
107 Dipiro P, Di Salvo DN, Fennessy FM, Howard SH, Jacene HA, Krajewski KM, Shinagare AB, Tirumani SH. CPI Adult Cancer Imaging Special Edition Module. Continuous Professional Improvement 2019. [DOI: 10.54057/cpi.ac2019] [Reference Citation Analysis]
108 Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Review of Hematology 2018;12:5-19. [DOI: 10.1080/17474086.2019.1558399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
109 Gilson D, Whittaker S, Child F, Scarisbrick J, Illidge T, Parry E, Mohd Mustapa M, Exton L, Kanfer E, Rezvani K, Dearden C, Morris S, Mchenry P, Leslie T, Wakelin S, Hunasehally R, Cork M, Johnston G, Chiang N, Worsnop F, Salim A, Buckley D, Petrof G, Callachand N, Flavell T, Salad A. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019;180:496-526. [DOI: 10.1111/bjd.17240] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 13.6] [Reference Citation Analysis]
110 Georgakopoulos I, Papadavid E, Platoni K, Dilvoi M, Patatoukas G, Kypraiou E, Nikolaou V, Efstathopoulos E, Kelekis N, Kouloulias V. Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule. Clin Transl Radiat Oncol 2019;15:26-30. [PMID: 30582018 DOI: 10.1016/j.ctro.2018.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
111 Scarisbrick J, Quaglino P, Prince H, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz‐romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram‐wolff C, Battistella M, Alberti‐violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot‐barry M, Pham‐ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel‐kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon‐pennamen M, Battistella M, Climent F, Gonzalez‐barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots A, Hauben E, Bervoets A, Woei‐a‐jin F, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, Mckay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches J, Miyashiro D, Akilov O, Mccann S, Sahi H, Damasco F, Querfeld C, Folkes A, Bur C, Klemke C, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019;181:350-7. [DOI: 10.1111/bjd.17258] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
112 Rivers CI, Singh AK. Total Skin Electron Beam Therapy for Mycosis Fungoides Revisited With Adjuvant Systemic Therapy. Clin Lymphoma Myeloma Leuk 2019;19:83-8. [PMID: 30528417 DOI: 10.1016/j.clml.2018.11.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Raghavan SS, Hong EK, Kim YH, Kim J. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. J Cutan Pathol 2019;46:33-43. [DOI: 10.1111/cup.13375] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
114 Blaizot R, Ouattara E, Fauconneau A, Beylot-barry M, Pham-ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol 2018;179:1322-8. [DOI: 10.1111/bjd.17073] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
115 Amorim GM, Corbellini JPN, Quintella DC, Cuzzi T, Ramos-E-Silva M. Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides. An Bras Dermatol 2018;93:680-5. [PMID: 30156617 DOI: 10.1590/abd1806-4841.20187134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
116 Lebowitz E, Geller S, Flores E, Pulitzer M, Horwitz S, Moskowitz A, Kheterpal M, Myskowski PL. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. J Eur Acad Dermatol Venereol 2019;33:108-14. [PMID: 30176169 DOI: 10.1111/jdv.15236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
117 Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol 2018;93:546-52. [PMID: 30066762 DOI: 10.1590/abd1806-4841.20187106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
118 Youssef R, Mahgoub D, Zeid OA, Abdel-Halim DM, El-Hawary M, Hussein MF, Morcos MA, Aboelfadl DM, Abdelkader HA, Abdel-Galeil Y, Abdel-Halim MRE. Hypopigmented Interface T-Cell Dyscrasia and Hypopigmented Mycosis Fungoides: A Comparative Study. Am J Dermatopathol 2018;40:727-35. [PMID: 30188378 DOI: 10.1097/DAD.0000000000001187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
119 Peñate Y, Servitje O, Machan S, Fernández-de-misa R, Estrach M, Acebo E, Mitxelena J, Ramón M, Flórez A, Blanes M, Morillo M, Medina S, Bassas J, Zayas A, Espinosa P, Pérez A, Gónzalez-romero N, Domínguez J, Muniesa C, López Robles J, Combalia A, Yanguas I, Suh H, Polo-rodríguez I, Bielsa I, Mateu A, Ferrer B, Descalzo M, García-doval I, Ortiz-romero P. Registro de linfomas cutáneos primarios de la AEDV: primer año de funcionamiento. Actas Dermo-Sifiliográficas 2018;109:610-6. [DOI: 10.1016/j.ad.2018.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
120 Peñate Y, Servitje O, Machan S, Fernández-de-misa R, Estrach M, Acebo E, Mitxelena J, Ramón M, Flórez A, Blanes M, Morillo M, Medina S, Bassas J, Zayas A, Espinosa P, Pérez A, Gónzalez-romero N, Domínguez J, Muniesa C, López Robles J, Combalia A, Yanguas I, Suh H, Polo-rodríguez I, Bielsa I, Mateu A, Ferrer B, Descalzo M, García-doval I, Ortiz-romero P. The First Year of the AEVD Primary Cutaneous Lymphoma Registry. Actas Dermo-Sifiliográficas (English Edition) 2018;109:610-616. [DOI: 10.1016/j.adengl.2018.06.003] [Reference Citation Analysis]
121 Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M;  MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192-1204. [PMID: 30100375 DOI: 10.1016/s1470-2045(18)30379-6] [Cited by in Crossref: 275] [Cited by in F6Publishing: 289] [Article Influence: 55.0] [Reference Citation Analysis]
122 Scarisbrick J. Staging of Mycosis Fungoides and Sézary Syndrome: Time for an Update? EMJ Hematol 2018. [DOI: 10.33590/emjhematol/10313097] [Reference Citation Analysis]
123 Prince HM, Querfeld C. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2018;31:322-35. [PMID: 30213403 DOI: 10.1016/j.beha.2018.07.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
124 Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs 2018;27:691-7. [DOI: 10.1080/13543784.2018.1498081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
125 Jang BS, Kim E, Kim IH, Kang HC, Ye SJ. Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution. Radiat Oncol J 2018;36:153-62. [PMID: 29983036 DOI: 10.3857/roj.2017.00542] [Reference Citation Analysis]
126 Wickenden K, Graham-Brown MPM, Veitch D, Dormer J, Bamford M, Graham-Brown RAC, Warwick G, Wagner S, Burton JO. Sézary Syndrome Presenting With Renal Involvement. Am J Kidney Dis 2018;72:890-4. [PMID: 29941220 DOI: 10.1053/j.ajkd.2018.04.013] [Reference Citation Analysis]
127 Dong Z, Zhu X, Li Y, Gan L, Chen H, Zhang W, Sun J. Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides. Medicine (Baltimore) 2018;97:e10871. [PMID: 29794791 DOI: 10.1097/MD.0000000000010871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
128 Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2017;28:2517-25. [PMID: 28961843 DOI: 10.1093/annonc/mdx352] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
129 Qiu L, Liu F, Yi S, Li X, Liu X, Xiao C, Lian CG, Tu P, Wang Y. Loss of 5-Hydroxymethylcytosine Is an Epigenetic Biomarker in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2018;138:2388-97. [PMID: 29803640 DOI: 10.1016/j.jid.2018.05.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
130 Wehkamp U, Weichenthal M, Egberts F, Schwarz T, Klapper W, Oschlies I. Clinically defined subgroups of mycosis fungoides display differing histopathological features at initial biopsy. Leuk Lymphoma 2018;59:2871-9. [PMID: 29616855 DOI: 10.1080/10428194.2018.1452218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
131 Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Curr Oncol Rep 2018;20:32. [PMID: 29572582 DOI: 10.1007/s11912-018-0678-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
132 Alexander-Savino CV, Hayden MS, Richardson C, Zhao J, Poligone B. Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells. Oncotarget 2016;7:75954-67. [PMID: 27732942 DOI: 10.18632/oncotarget.12488] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
133 Ruiz R, Morante Z, Mantilla R, Mas L, Casanova L, Gomez HL. Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute. An Bras Dermatol 2017;92:649-54. [PMID: 29166501 DOI: 10.1590/abd1806-4841.20176825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
134 Ferrara G, Chiarelli C, Simonetti S. B-cell Lymphofollicular Infiltrates in Mycosis Fungoides. Tumori 2010;96:487-91. [DOI: 10.1177/030089161009600319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
135 Finn WG, Macon WR. Mature T-Cell and Natural Killer–Cell Leukemias. Hematopathology 2018. [DOI: 10.1016/b978-0-323-47913-4.00013-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
136 Lemchak D, Banerjee S, Digambar SS, Hood BL, Conrads TP, Jedrych J, Geskin L, Akilov OE. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 2018;27:188-90. [PMID: 29205518 DOI: 10.1111/exd.13477] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
137 Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. Journal of Dermatological Treatment 2018;29:522-30. [DOI: 10.1080/09546634.2017.1412064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
138 Ghazawi FM, Netchiporouk E, Rahme E, Tsang M, Moreau L, Glassman S, Provost N, Gilbert M, Jean SE, Roshdy O, Pehr K, Sasseville D, Litvinov IV. Distribution and Clustering of Cutaneous T-Cell Lymphoma (CTCL) Cases in Canada During 1992 to 2010. J Cutan Med Surg 2018;22:154-65. [PMID: 29241349 DOI: 10.1177/1203475417745825] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
139 Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2016;16 Suppl:S181-S190.e4. [PMID: 27521316 DOI: 10.1016/j.clml.2016.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
140 Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
141 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
142 Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Xiao R, Karakousis G, Zhang PJ, Zhang G. Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. Journal of the American Academy of Dermatology 2017;77:497-502.e2. [DOI: 10.1016/j.jaad.2017.04.1137] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
143 Martinez-escala ME, Kantor RW, Cices A, Zhou XA, Kaplan JB, Pro B, Choi J, Guitart J. CD8 + mycosis fungoides: A low-grade lymphoproliferative disorder. Journal of the American Academy of Dermatology 2017;77:489-96. [DOI: 10.1016/j.jaad.2017.05.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
144 Almohideb M, Walsh S, Walsh S, Shear N, Alhusayen R. Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clinical Lymphoma Myeloma and Leukemia 2017;17:604-12. [DOI: 10.1016/j.clml.2017.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
145 Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The Diagnosis, Staging, and Treatment Options for Mycosis Fungoides. Cancer Control 2007;14:102-11. [DOI: 10.1177/107327480701400203] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
146 Hoot JW, Wang L, Kho T, Akilov OE. The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatolog Treat 2018;29:272-6. [PMID: 28782389 DOI: 10.1080/09546634.2017.1365113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
147 Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30 + primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol 2017;56:1400-5. [DOI: 10.1111/ijd.13696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
148 Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther 2017;16:2304-14. [PMID: 28729399 DOI: 10.1158/1535-7163.MCT-17-0060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
149 Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, Curry JL, Nagarajan P, Ivan D, Prieto VG, Medeiros LJ, Duvic M, Torres-Cabala CA. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas. Am J Surg Pathol 2017;41:204-15. [PMID: 27879514 DOI: 10.1097/PAS.0000000000000768] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
150 Binamer Y. Cutaneous T-cell lymphoma in Saudi Arabia: retrospective single-center review. Ann Saudi Med 2017;37:212-5. [PMID: 28578360 DOI: 10.5144/0256-4947.2017.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
151 Heitmiller K, Barnes J, Chen ST. Cutaneous Lymphoma—Inpatient Considerations. Curr Derm Rep 2017;6:63-76. [DOI: 10.1007/s13671-017-0173-x] [Reference Citation Analysis]
152 Ul-Haq Z, Effendi JS, Ashraf S, Bkhaitan MM. Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors. J Mol Graph Model 2017;74:379-95. [PMID: 28499271 DOI: 10.1016/j.jmgm.2017.03.016] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Ghazawi FM, Netchiporouk E, Rahme E, Tsang M, Moreau L, Glassman S, Provost N, Gilbert M, Jean S, Pehr K, Sasseville D, Litvinov IV. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy: CTCL Incidence and Mortality in Canada. Cancer 2017;123:3550-67. [DOI: 10.1002/cncr.30758] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
154 Zhukov AS, Telichko IN, Belousova IE, Samcov AV. Assessment of prognostic predictive value at the mycosis fungoides. Vestnik dermatologii i venerologii 2017;93:20-26. [DOI: 10.25208/0042-4609-2017-93-2-20-26] [Reference Citation Analysis]
155 Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, Koletsa T, Georgiou E, Pappa V, Stratigos A, Antoniou C. Prognostic indicators for mycosis fungoides in a Greek population. Br J Dermatol 2017;176:1321-30. [DOI: 10.1111/bjd.15000] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
156 Thompson AK, Killian JM, Weaver AL, Pittelkow MR, Davis MD. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. Journal of the American Academy of Dermatology 2017;76:683-8. [DOI: 10.1016/j.jaad.2016.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
157 Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol 2017;132:439-46. [PMID: 28271282 DOI: 10.1007/s11060-017-2389-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
158 Hoppe RT, Kim YH, Advani RH. Mycosis Fungoides and Sézary Syndrome. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm121] [Reference Citation Analysis]
159 Dulmage B, Geskin L, Guitart J, Akilov OE. The biomarker landscape in mycosis fungoides and Sézary syndrome. Exp Dermatol 2017;26:668-76. [PMID: 27897325 DOI: 10.1111/exd.13261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
160 Kelati A, Gallouj S, Tahiri L, Harmouche T, Mernissi FZ. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. Int J Womens Dermatol 2017;3:100-6. [PMID: 28560304 DOI: 10.1016/j.ijwd.2016.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
161 Mpakou V, Papadavid E, Kontsioti F, Konsta E, Vikentiou M, Spathis A, Papageorgiou S, Vasilatou D, Gkontopoulos K, Mpazani E, Karakitsos P, Rigopoulos D, Dimitriadis G, Pappa V. Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. PLoS One 2017;12:e0170186. [PMID: 28107479 DOI: 10.1371/journal.pone.0170186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
162 Odum N, Lindahl LM, Wod M, Krejsgaard T, Skytthe A, Woetmann A, Iversen L, Christensen K. Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. Blood Cancer J 2017;7:e517. [PMID: 28106877 DOI: 10.1038/bcj.2016.128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
163 Cedeno-Laurent F, Wysocka M, Obstfeld AE, Novoa RA, Vittorio CC, Kim EJ, Weng WK, Rook AH. Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides. J Cutan Pathol 2017;44:462-6. [PMID: 28083948 DOI: 10.1111/cup.12899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
164 Park HS, McIntosh L, Braschi-Amirfarzan M, Shinagare AB, Krajewski KM. T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. Korean J Radiol 2017;18:71-83. [PMID: 28096719 DOI: 10.3348/kjr.2017.18.1.71] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
165 Raychaudhury T. Management Strategies for Mycosis Fungoides in India. Indian J Dermatol 2017;62:137-41. [PMID: 28400632 DOI: 10.4103/ijd.IJD_71_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
166 Mc O. Primary Cutaneous Lymphomas and Interferon Treatment. J Hematol Clin Res 2017;1:001-010. [DOI: 10.29328/journal.jhcr.1001001] [Reference Citation Analysis]
167 Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Expert Review of Hematology 2017;10:111-21. [DOI: 10.1080/17474086.2017.1270201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
168 Hanel W, Briski R, Ross CW, Anderson TF, Kaminski MS, Hristov AC, Wilcox RA. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol 2016;91:E491-5. [PMID: 27649045 DOI: 10.1002/ajh.24564] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
169 Ferenczi K, Makkar HS. Cutaneous lymphoma: Kids are not just little people. Clinics in Dermatology 2016;34:749-59. [DOI: 10.1016/j.clindermatol.2016.07.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
170 Boonk SE, Zoutman WH, Putter H, Ram-Wolff C, Felcht M, Klemke CD, Ranki A, Quaglino P, Whittaker S, Bagot M, Willemze R, Vermeer MH. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome. J Invest Dermatol 2017;137:754-7. [PMID: 27984038 DOI: 10.1016/j.jid.2016.10.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
171 Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology Am Soc Hematol Educ Program 2015;2015:529-44. [PMID: 26637769 DOI: 10.1182/asheducation-2015.1.529] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
172 Biskup E, Naym DG, Gniadecki R. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. J Dermatol Sci 2016;84:239-47. [PMID: 27743911 DOI: 10.1016/j.jdermsci.2016.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
173 Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, Teague JE, Gehad A, Lowry EL, LeBoeuf NR, Krueger JG, Robins HS, Kupper TS, Clark RA. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 2015;7:308ra158. [PMID: 26446955 DOI: 10.1126/scitranslmed.aaa9122] [Cited by in Crossref: 129] [Cited by in F6Publishing: 132] [Article Influence: 18.4] [Reference Citation Analysis]
174 Cozzolino I, Rocco M, Villani G, Picardi M. Lymph Node Fine-Needle Cytology of Non-Hodgkin Lymphoma: Diagnosis and Classification by Flow Cytometry. Acta Cytol 2016;60:302-14. [PMID: 27554776 DOI: 10.1159/000448389] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
175 Cieza-Díaz DE, Conde-Montero E, Menarguez-Palanca J, Longo-Imedio I. Epidemiological and clinical features of patients diagnosed with cutaneous T-cell lymphomas in a Spanish tertiary care hospital. J Eur Acad Dermatol Venereol 2017;31:e150-3. [PMID: 27518589 DOI: 10.1111/jdv.13914] [Reference Citation Analysis]
176 Charli-Joseph YV, Gatica-Torres M, Pincus LB. Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma? Indian J Dermatol 2016;61:351-74. [PMID: 27512181 DOI: 10.4103/0019-5154.185698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
177 McGirt LY, Degesys CA, Johnson VE, Zic JA, Zwerner JP, Eischen CM. TOX expression and role in CTCL. J Eur Acad Dermatol Venereol 2016;30:1497-502. [PMID: 27345620 DOI: 10.1111/jdv.13651] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
178 Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood 2016;127:3142-53. [DOI: 10.1182/blood-2015-12-611830] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 11.0] [Reference Citation Analysis]
179 Sanz-bueno J, Lora D, Monsálvez V, Maroñas-jiménez L, Postigo C, Rodríguez- Peralto J, Ortiz-romero P. The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. Br J Dermatol 2016;175:794-6. [DOI: 10.1111/bjd.14559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
180 Tagami T, Alhalabi O, Ward N, Huang J. Paraneoplastic Dermatosis in a Patient with Anaplastic Large-Cell Lymphoma: Case Report and Literature Review. Dermatopathology (Basel) 2016;3:39-43. [PMID: 27504444 DOI: 10.1159/000445766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
181 Ceriolo P, Fausti V, Cinotti E, Bonadio S, Raffaghello L, Bianchi G, Orcioni GF, Fiocca R, Rongioletti F, Pistoia V, Borgonovo G. Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. World J Gastroenterol 2016; 22(12): 3496-3501 [PMID: 27022231 DOI: 10.3748/wjg.v22.i12.3496] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
182 Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. J Am Acad Dermatol 2016;74:870-7. [PMID: 26874819 DOI: 10.1016/j.jaad.2015.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
183 Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T-cell lymphomas. Curr Opin Oncol 2016;28:166-71. [PMID: 26844985 DOI: 10.1097/CCO.0000000000000272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
184 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
185 Naeini FF, Abtahi-Naeini B, Pourazizi M, Sadeghiyan H, Najafian J. Primary cutaneous lymphomas: A clinical and histological study of 99 cases in Isfahan, Iran. J Res Med Sci 2015;20:827-31. [PMID: 26759567 DOI: 10.4103/1735-1995.170595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
186 Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, Nastasi C, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Kilian M, Koralov SB, Odum N. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood 2016;127:1287-96. [PMID: 26738536 DOI: 10.1182/blood-2015-08-662353] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 9.6] [Reference Citation Analysis]
187 Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 2016;99:228-40. [PMID: 26811014 DOI: 10.1016/j.critrevonc.2015.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
188 Goldinger SM, Guenova E, Fujii K, Urosevic-maiwald M. Cutaneous Lymphomas. Immunology of the Skin 2016. [DOI: 10.1007/978-4-431-55855-2_29] [Reference Citation Analysis]
189 Kaffenberger BH, Bechtel MA, Porcu P. The Therapy of Cutaneous T Cell Lymphoma. The Cutaneous Lymphoid Proliferations 2016. [DOI: 10.1002/9781118776193.ch2] [Reference Citation Analysis]
190 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
191 Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkötter C, Eich HT. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics 2015;93:1077-86. [DOI: 10.1016/j.ijrobp.2015.08.041] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
192 Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, Xi L, Meng Q, Langridge T, Drummond J, Donehower LA, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Duvic M. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015;47:1426-34. [PMID: 26551670 DOI: 10.1038/ng.3444] [Cited by in Crossref: 218] [Cited by in F6Publishing: 225] [Article Influence: 27.3] [Reference Citation Analysis]
193 Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, Lim HW. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2016;74:27-58. [PMID: 26547257 DOI: 10.1016/j.jaad.2015.09.033] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 11.3] [Reference Citation Analysis]
194 Mahalingam M, Reddy VB. Mycosis Fungoides, Then and Now… Have We Travelled? Adv Anat Pathol 2015;22:376-83. [PMID: 26452212 DOI: 10.1097/PAP.0000000000000092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Hurabielle C, Ingen-housz-oro S, Ortonne N, Cornillet-lefèbvre P, Merah A, D'incan M, Joly P, Franck N, Estève E, Maubec E, Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L, Michel C, Quereux G, Saiag P, Ram-wolff C, Lenormand B, Wechsler J, Bastuji-garin S, Bagot M, Delfau-larue M. Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. Br J Dermatol 2015;173:1015-23. [DOI: 10.1111/bjd.14017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
196 Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 2015;33:3766-73. [PMID: 26438120 DOI: 10.1200/JCO.2015.61.7142] [Cited by in Crossref: 243] [Cited by in F6Publishing: 256] [Article Influence: 30.4] [Reference Citation Analysis]
197 Geskin LJ. Monoclonal Antibodies. Dermatologic Clinics 2015;33:777-86. [DOI: 10.1016/j.det.2015.05.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
198 Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. Dermatologic Clinics 2015;33:807-18. [DOI: 10.1016/j.det.2015.05.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
199 Chung CG, Poligone B. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma. Dermatologic Clinics 2015;33:787-805. [DOI: 10.1016/j.det.2015.05.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
200 Nguyen CV, Bohjanen KA. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. Dermatologic Clinics 2015;33:683-96. [DOI: 10.1016/j.det.2015.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
201 Clark RA. Resident memory T cells in human health and disease. Sci Transl Med 2015;7:269rv1. [PMID: 25568072 DOI: 10.1126/scitranslmed.3010641] [Cited by in Crossref: 264] [Cited by in F6Publishing: 271] [Article Influence: 33.0] [Reference Citation Analysis]
202 Wernham A, Shah F, Amel-kashipaz R, Cobbold M, Scarisbrick J. Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. Br J Dermatol 2015;173:1295-7. [DOI: 10.1111/bjd.13939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
203 Poligone B, Querfeld C. Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team. Br J Dermatol 2015;173:1081-3. [PMID: 25894580 DOI: 10.1111/bjd.13849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
204 Reidel U, Bechstein S, Lange-Asschenfeldt B, Beyer M, Vandersee S. Treatment of localized mycosis fungoides with digital UV photochemotherapy. Photodermatol Photoimmunol Photomed 2015;31:333-40. [PMID: 26284356 DOI: 10.1111/phpp.12196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
205 DeSesa CR, Appugounder S, Haberland C, Johnson MP. Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma. J Oral Maxillofac Surg 2016;74:292-301. [PMID: 26296596 DOI: 10.1016/j.joms.2015.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
206 Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 2015;126:1452-61. [PMID: 26228486 DOI: 10.1182/blood-2015-02-630335] [Cited by in Crossref: 132] [Cited by in F6Publishing: 137] [Article Influence: 16.5] [Reference Citation Analysis]
207 Tan E, Shao H, Friedman M. Mycosis Fungoides of the Rectum: Case Report and Review of the Literature. J Gastrointest Cancer 2016;47:417-9. [PMID: 26195195 DOI: 10.1007/s12029-015-9751-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
208 Chowdhary M, Kabbani AA, Rimtepathip P, Cole DA Jr, Cohen DJ. Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapy. Onco Targets Ther 2015;8:1597-601. [PMID: 26170695 DOI: 10.2147/OTT.S87219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
209 Case 66. Practical Flow Cytometry in Haematology Diagnosis 2015. [DOI: 10.1002/9781118746950.ch66] [Reference Citation Analysis]
210 McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015;126:508-19. [PMID: 26082451 DOI: 10.1182/blood-2014-11-611194] [Cited by in Crossref: 147] [Cited by in F6Publishing: 156] [Article Influence: 18.4] [Reference Citation Analysis]
211 Alberti-violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment. Clinical Lymphoma Myeloma and Leukemia 2015;15:e105-12. [DOI: 10.1016/j.clml.2015.02.027] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
212 Hughes CF, Newland K, Mccormack C, Lade S, Prince HM. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers: Mycosis fungoides and Sézary syndrome. Australasian Journal of Dermatology 2016;57:182-91. [DOI: 10.1111/ajd.12349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
213 Hamada T, Iwatsuki K. Cutaneous lymphoma in Japan: a nationwide study of 1733 patients. J Dermatol 2014;41:3-10. [PMID: 24438138 DOI: 10.1111/1346-8138.12299] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
214 Brazzelli V, Rivetti N, Badulli C, Carugno A, Cananzi R, De Silvestri A, Martinetti M, Borroni G. Mycosis fungoides: association of KIR ligands and HLA-DQB1*05 with bad prognosis of the disease. J Eur Acad Dermatol Venereol 2016;30:266-9. [DOI: 10.1111/jdv.13083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
215 Kempf W, Kazakov DV, Belousova IE, Mitteldorf C, Kerl K. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. J Eur Acad Dermatol Venereol 2015;29:1696-709. [PMID: 25715748 DOI: 10.1111/jdv.13044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
216 Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort. Journal of the American Academy of Dermatology 2015;72:276-85. [DOI: 10.1016/j.jaad.2014.10.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
217 Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology 2015;72:286-92. [DOI: 10.1016/j.jaad.2014.10.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 14.4] [Reference Citation Analysis]
218 Fatemi Naeini F, Abtahi-Naeini B, Sadeghiyan H, Nilforoushzadeh MA, Najafian J, Pourazizi M. Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study. J Skin Cancer 2015;2015:306543. [PMID: 25694829 DOI: 10.1155/2015/306543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
219 Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 2015;125:2798-805. [PMID: 25628470 DOI: 10.1182/blood-2014-07-590398] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 11.1] [Reference Citation Analysis]
220 Eder J, Kern A, Moser J, Kitzwögerer M, Sedivy R, Trautinger F. Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. J Eur Acad Dermatol Venereol 2015;29:1517-23. [PMID: 25600184 DOI: 10.1111/jdv.12907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
221 Aviles A, Neri N, Fernandez-diez J, Silva L, Nambo M. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology 2015;20:538-42. [DOI: 10.1179/1607845415y.0000000002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
222 Boonk SE, Putter H, Koolhof L, Willemze R, Vermeer MH. Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides. Br J Dermatol 2014;170:1080-6. [PMID: 24299563 DOI: 10.1111/bjd.12763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
223 Wong HK, Wu L, de Silva S, Porcu P, Mishra A. Cutaneous T-Cell Lymphoma. Epigenetics and Dermatology 2015. [DOI: 10.1016/b978-0-12-800957-4.00017-5] [Reference Citation Analysis]
224 Shiratori S, Fujimoto K, Nishimura M, Hatanaka KC, Kosugi-kanaya M, Okada K, Sugita J, Shigematsu A, Hashimoto D, Endo T, Kondo T, Abe R, Hashino S, Matsuno Y, Shimizu H, Teshima T. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome: RIC-HSCT for MF/SS. Hematol Oncol 2016;34:9-16. [DOI: 10.1002/hon.2162] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
225 Dulmage BO, Geskin LJ. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol 2013;169:1188-97. [PMID: 23937674 DOI: 10.1111/bjd.12578] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
226 Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:837-51. [PMID: 25042790 DOI: 10.1002/ajh.23756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
227 Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides. Clinical Lymphoma Myeloma and Leukemia 2014;14:297-304. [DOI: 10.1016/j.clml.2014.01.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
228 De Marchi SU, Stinco G, Errichetti E, Bonin S, di Meo N, Trevisan G. The influence of the coexpression of CD4 and CD8 in cutaneous lesions on prognosis of mycosis fungoides: a preliminary study. J Skin Cancer 2014;2014:624143. [PMID: 25143835 DOI: 10.1155/2014/624143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
229 Humme D, Nast A, Erdmann R, Vandersee S, Beyer M. Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev 2014;40:927-33. [PMID: 24997678 DOI: 10.1016/j.ctrv.2014.06.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
230 Scarisbrick J, Kim Y, Whittaker S, Wood G, Vermeer M, Prince H, Quaglino P. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 2014;170:1226-36. [DOI: 10.1111/bjd.12909] [Cited by in Crossref: 91] [Cited by in F6Publishing: 100] [Article Influence: 10.1] [Reference Citation Analysis]
231 Ferrara G, Pancione M, Votino C, Quaglino P, Tomasini C, Santucci M, Pimpinelli N, Cusano F, Sabatino L, Colantuoni V. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. Br J Dermatol 2014;170:1266-75. [PMID: 24641245 DOI: 10.1111/bjd.12717] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
232 Pincus LB. Mycosis Fungoides. Surgical Pathology Clinics 2014;7:143-67. [DOI: 10.1016/j.path.2014.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
233 Kubica AW, Pittelkow MR. Sézary Syndrome. Surg Pathol Clin 2014;7:191-202. [PMID: 26837198 DOI: 10.1016/j.path.2014.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
234 Heng YK, Koh MJA, Giam YC, Tang MBY, Chong WS, Tan SH. Pediatric Mycosis Fungoides in Singapore: A Series of 46 Children. Pediatric Dermatology 2014;31:477-82. [DOI: 10.1111/pde.12352] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
235 Wu P, Huang V, Bigby M. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review. Br J Dermatol 2014;170:1015-20. [DOI: 10.1111/bjd.12954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
236 Lindahl LM, Fenger-Grøn M, Iversen L. Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: a Danish nationwide, population-based cohort study. J Am Acad Dermatol. 2014;71:529-535. [PMID: 24836079 DOI: 10.1016/j.jaad.2014.03.044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
237 Vollmer RT. A review of survival in mycosis fungoides. Am J Clin Pathol 2014;141:706-11. [PMID: 24713743 DOI: 10.1309/AJCPH2PHXFCX3BOX] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
238 Mycosis Fungoides. Skin Lymphoma 2014. [DOI: 10.1002/9781118492505.ch2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
239 Sézary Syndrome. Skin Lymphoma 2014. [DOI: 10.1002/9781118492505.ch3] [Reference Citation Analysis]
240 Brisou G, Manzoni D, Dalle S, Felman P, Morel D, Boubaya M, Magaud JP, Baseggio L. Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells. J Clin Lab Anal 2015;29:153-61. [PMID: 24652675 DOI: 10.1002/jcla.21744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
241 Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70:223.e1-217.e1; quiz 240-242. [PMID: 24438970 DOI: 10.1016/j.jaad.2013.08.033] [Cited by in Crossref: 188] [Cited by in F6Publishing: 206] [Article Influence: 20.9] [Reference Citation Analysis]
242 Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157-63. [PMID: 24616310 DOI: 10.1200/JCO.2013.52.0924] [Cited by in Crossref: 257] [Cited by in F6Publishing: 267] [Article Influence: 28.6] [Reference Citation Analysis]
243 Brazzelli V, Rivetti N, Badulli C, Carugno A, Grasso V, De Silvestri A, Martinetti M, Borroni G. Immunogenetic factors in mycosis fungoides: can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients. J Eur Acad Dermatol Venereol 2014;28:1732-7. [DOI: 10.1111/jdv.12391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
244 Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Journal of the American Academy of Dermatology 2014;70:205.e1-205.e16. [DOI: 10.1016/j.jaad.2013.07.049] [Cited by in Crossref: 188] [Cited by in F6Publishing: 171] [Article Influence: 20.9] [Reference Citation Analysis]
245 Sung JJ, Ververis K, Karagiannis TC. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. J Photochem Photobiol B 2014;131:104-12. [PMID: 24518645 DOI: 10.1016/j.jphotobiol.2014.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
246 Vigliar E, Cozzolino I, Picardi M, Peluso AL, Fernandez LV, Vetrani A, Botti G, Pane F, Selleri C, Zeppa P. Lymph node fine needle cytology in the staging and follow-up of cutaneous lymphomas. BMC Cancer 2014;14:8. [PMID: 24393425 DOI: 10.1186/1471-2407-14-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
247 Hansen L. Mycosis Fungoides☆. Reference Module in Biomedical Sciences 2014. [DOI: 10.1016/b978-0-12-801238-3.05166-7] [Reference Citation Analysis]
248 Fatemi Naeini F, Sadeghiyan H, Pourazizi M, Najafian J, Abtahi-Naeini B. Characteristics of Primary Cutaneous T-Cell Lymphoma in Iran: A 10-Year Retrospective Study. Int Sch Res Notices 2014;2014:820921. [PMID: 27437467 DOI: 10.1155/2014/820921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
249 Kun L, Hernandez-ilizaliturri FJ, Reddy NM. Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced Stages. Seminars in Hematology 2014;51:35-41. [DOI: 10.1053/j.seminhematol.2013.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
250 Querfeld C, Rosen ST. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00107-7] [Reference Citation Analysis]
251 Atalla A, Hallack Neto AE, Siqueira DB, Toledo GC. Allogeneic hematopoietic stem cell transplantation in mycosis fungoides. An Bras Dermatol 2013;88:216-9. [PMID: 24346924 DOI: 10.1590/abd1806-4841.20132365] [Reference Citation Analysis]
252 McGraw AL. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm 2013;70:1115-22. [PMID: 23784158 DOI: 10.2146/ajhp120163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
253 Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol 2014;67:431-6. [PMID: 24319102 DOI: 10.1136/jclinpath-2013-201748] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
254 Weng W, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. Science Translational Medicine 2013;5:214ra171-214ra171. [DOI: 10.1126/scitranslmed.3007420] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 6.9] [Reference Citation Analysis]
255 Peck JR, Frank MP, Peck LR. Was treatment the trigger? Mycosis fungoides. Am J Med 2013;126:1048-9. [PMID: 24083643 DOI: 10.1016/j.amjmed.2013.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
256 Tensen CP. MicroRNA Expression in Cutaneous T-Cell Lymphomas. MicroRNAs in Medicine 2013. [DOI: 10.1002/9781118300312.ch27] [Reference Citation Analysis]
257 Yosifov DY, Kaloyanov KA, Guenova ML, Prisadashka K, Balabanova MB, Berger MR, Konstantinov SM. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res 2014;38:49-56. [PMID: 24225136 DOI: 10.1016/j.leukres.2013.10.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
258 Moraes FY, Carvalho Hde A, Hanna SA, Silva JL, Marta GN. Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults. Rep Pract Oncol Radiother 2014;19:92-8. [PMID: 24936326 DOI: 10.1016/j.rpor.2013.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
259 Quéreux G, Brocard A, Saint-Jean M, Peuvrel L, Knol AC, Allix R, Khammari A, Renaut JJ, Dréno B. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013;69:890-7. [PMID: 24041738 DOI: 10.1016/j.jaad.2013.07.047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
260 Tobisawa S, Honma M, Ishida-yamamoto A, Saijo Y, Iizuka H. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: Clusterin expression as a novel prognostic factor. Journal of Dermatological Science 2013;71:160-6. [DOI: 10.1016/j.jdermsci.2013.04.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
261 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
262 Boos MD, Samimi SS, Rook AH, Yan AC, Kim EJ. Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children. Curr Derm Rep 2013;2:203-11. [DOI: 10.1007/s13671-013-0054-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
263 Biskup E, Kamstrup MR, Manfé V, Gniadecki R. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma. Br J Dermatol 2013;168:504-12. [PMID: 23445313 DOI: 10.1111/bjd.12071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
264 Nakaike T, Kato K, Oku S, Hayashi M, Kikushige Y, Kuroiwa M, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Ohshima K, Akashi K. Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. Int J Hematol 2013;98:491-5. [DOI: 10.1007/s12185-013-1410-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
265 Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, Parmiggiani M, Barbieri P, Bertoni F. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Rep Pract Oncol Radiother 2014;19:77-91. [PMID: 24936325 DOI: 10.1016/j.rpor.2013.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
266 Duvic M, Geskin L, Prince HM. Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. Clinical Lymphoma Myeloma and Leukemia 2013;13:377-84. [DOI: 10.1016/j.clml.2013.02.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
267 Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539-2549. [PMID: 23886836 DOI: 10.1182/blood-2013-06-507947] [Cited by in Crossref: 539] [Cited by in F6Publishing: 563] [Article Influence: 53.9] [Reference Citation Analysis]
268 Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, Woetmann A, Zhou Y, Sasseville D, Odum N. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013;122:943-50. [PMID: 23801634 DOI: 10.1182/blood-2013-01-480889] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
269 Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49:2859-2868. [PMID: 23735705 DOI: 10.1016/j.ejca.2013.04.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
270 Calderon Cabrera C, de la Cruz Vicente F, Marín-niebla A, Carrillo Cruz E, Rios Herranz E, Espigado Tocino I, Prats Martín C, Falantes JF, Martino Galiana ML, Perez-simón JA. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/sezary syndrome. Br J Haematol 2013;162:130-2. [DOI: 10.1111/bjh.12320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
271 Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013;139:466-90. [PMID: 23525617 DOI: 10.1309/AJCPOBDP2OQAJ5BR] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
272 Lehloenya RJ, Shebe K, Hlela C, Dlamini S, Mankahla A, Lapiner V, Meintjes G, Todd G. Aggressive worsening of Sézary syndrome during early antiretroviral therapy. AIDS 2013;27:1035-6. [PMID: 23698068 DOI: 10.1097/QAD.0b013e32835ecb62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
273 Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013;149:25-32. [PMID: 23069814 DOI: 10.1001/2013.jamadermatol.541] [Cited by in Crossref: 104] [Cited by in F6Publishing: 110] [Article Influence: 10.4] [Reference Citation Analysis]
274 Samimi S, Rook AH, Kim EJ. Update on Epidemiology of Cutaneous T-Cell Lymphoma. Curr Derm Rep 2013;2:35-41. [DOI: 10.1007/s13671-012-0038-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
275 Duvic M. Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome. Lymphoma 2013. [DOI: 10.1007/978-1-62703-408-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
276 Kelsey CR, Wilson LD. Lymphoma. Decision Tools for Radiation Oncology 2013. [DOI: 10.1007/174_2013_830] [Reference Citation Analysis]
277 Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, Scarisbrick J, Beynon T. Prevalence and Severity of Pruritus and Quality of Life in Patients With Cutaneous T-Cell Lymphoma. Journal of Pain and Symptom Management 2013;45:114-9. [DOI: 10.1016/j.jpainsymman.2012.01.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
278 Hoppe BS, Mendenhall NP. Radiation Therapy of Cutaneous Lymphoma. Radiation Therapy for Skin Cancer 2013. [DOI: 10.1007/978-1-4614-6986-5_17] [Reference Citation Analysis]
279 Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 2013;85:21-31. [DOI: 10.1016/j.critrevonc.2012.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
280 Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR. Sézary syndrome: A study of 176 patients at Mayo Clinic. Journal of the American Academy of Dermatology 2012;67:1189-99. [DOI: 10.1016/j.jaad.2012.04.043] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
281 Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R. Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012. JCO 2012;30:4091-7. [DOI: 10.1200/jco.2011.39.8065] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
282 Booken N, Nicolay JP, Weiss C, Klemke C. Cutaneous tumor cell load correlates with survival in patients with Sézary syndrome. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013;11:67-79. [DOI: 10.1111/j.1610-0387.2012.08027.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
283 Drews RE. Emerging Treatment Options for Advanced-Stage Mycosis Fungoides. JCO 2012;30:4064-70. [DOI: 10.1200/jco.2012.44.5650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
284 AlGhamdi KM, Arafah MM, Al-Mubarak LA, Khachemoune A, Al-Saif FM. Profile of mycosis fungoides in 43 Saudi patients. Ann Saudi Med 2012;32:283-7. [PMID: 22588440 DOI: 10.5144/0256-4947.2012.283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
285 Weberschock T, Strametz R, Lorenz M, Röllig C, Bunch C, Bauer A, Schmitt J. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012;:CD008946. [PMID: 22972128 DOI: 10.1002/14651858.CD008946.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
286 Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis: Long-term treatment of CTCL with ECP. Photodermatol Photoimmunol Photomed 2012;28:250-7. [DOI: 10.1111/j.1600-0781.2012.00689.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
287 Kim M, Thompson LA, Wenger SD, O'bryant CL. Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma. Ann Pharmacother 2012;46:1340-8. [DOI: 10.1345/aph.1r036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
288 Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, Weng WK, Aros CJ, Mah A, Chen RO. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood. 2012;120:3288-3297. [PMID: 22936659 DOI: 10.1182/blood-2012-04-423061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 5.8] [Reference Citation Analysis]
289 Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00: PUVA vs. PUVA and bexarotene for treatment of MF. British Journal of Dermatology 2012;167:678-87. [DOI: 10.1111/j.1365-2133.2012.11156.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
290 Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, Tokura Y, Nozaki K, Izutsu K, Suzuki R, Setoyama M, Nagatani T, Koga H, Tani M, Iwatsuki K. Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group. J Dermatol 2013;40:2-14. [DOI: 10.1111/j.1346-8138.2012.01639.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
291 Guo W, Liu R, Ono Y, Ma AH, Martinez A, Sanchez E, Wang Y, Huang W, Mazloom A, Li J, Ning J, Maverakis E, Lam KS, Kung HJ. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol Pharmacol 2012;82:938-47. [PMID: 22899868 DOI: 10.1124/mol.112.079889] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
292 Chang DK, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell JJ, Zhu Q, Kupper TS, Marasco WA. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther 2012;11:2451-61. [PMID: 22869555 DOI: 10.1158/1535-7163.MCT-12-0278] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
293 van Kester MS, Borg MK, Zoutman WH, Out-luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R, Willemze R, Tensen CP. A Meta-Analysis of Gene Expression Data Identifies a Molecular Signature Characteristic for Tumor-Stage Mycosis Fungoides. Journal of Investigative Dermatology 2012;132:2050-9. [DOI: 10.1038/jid.2012.117] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
294 Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18:5051-5060. [PMID: 22850569 DOI: 10.1158/1078-0432.ccr-12-0604] [Cited by in Crossref: 195] [Cited by in F6Publishing: 201] [Article Influence: 17.7] [Reference Citation Analysis]
295 Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 2012;16:195-204. [PMID: 22459529 DOI: 10.1188/12.CJON.195-204] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
296 Duhovic C, Child F, Wain EM. Management of cutaneous T-cell lymphoma. Clin Med (Lond) 2012;12:160-4. [PMID: 22586794 DOI: 10.7861/clinmedicine.12-2-160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
297 Quaglino P, Pimpinelli N, Berti E, Calzavara-pinton P, Alfonso Lombardo G, Rupoli S, Alaibac M, Bottoni U, Carbone A, Fava P, Fimiani M, Mamusa AM, Titli S, Zinzani PL, Bernengo MG; on behalf of the Gruppo Italiano Linfomi Cutanei (GILC). Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012;118:5830-9. [DOI: 10.1002/cncr.27627] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
298 Terhorst D, Mestel D, Humme D, Sterry W, Beyer M. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas: Follow-up examinations in patients with indolent primary cutaneous lymphomas. British Journal of Dermatology 2012;166:1295-300. [DOI: 10.1111/j.1365-2133.2012.10896.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
299 Jain S, Zain J, O'Connor O. Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol 2012;5:24. [PMID: 22594538 DOI: 10.1186/1756-8722-5-24] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
300 Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, Dorosario AA, Chaney KS, Cutler CS, Leboeuf NR, Carter JB, Fisher DC, Kupper TS. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4:117ra7. [PMID: 22261031 DOI: 10.1126/scitranslmed.3003008] [Cited by in Crossref: 267] [Cited by in F6Publishing: 279] [Article Influence: 24.3] [Reference Citation Analysis]
301 Khawaja MR, Mark L, Alexander RE, Nassiri M, Azar J. Mycosis fungoides with testicular involvement: a rare phenomenon. Leuk Res 2012;36:e149-52. [PMID: 22560335 DOI: 10.1016/j.leukres.2012.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119:4115-22. [DOI: 10.1182/blood-2011-11-390211] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 8.7] [Reference Citation Analysis]
303 Wada H, Tsuboi R, Kato Y, Sugaya M, Tobinai K, Hamada T, Shimamoto T, Noguchi K, Iwatsuki K. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. J Dermatol 2012;39:823-8. [PMID: 22506596 DOI: 10.1111/j.1346-8138.2012.01554.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
304 Dalton SR, Hicks M, Shabanowitz R, Elston DM. Ethical dilemmas in the management of tumor-stage mycosis fungoides in a pregnant patient. J Am Acad Dermatol 2012;66:661-3. [PMID: 22421113 DOI: 10.1016/j.jaad.2011.11.952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75-89. [PMID: 22457602 DOI: 10.2147/CMAR.S9660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
306 Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. Am J Clin Pathol 2012;137:403-11. [PMID: 22338052 DOI: 10.1309/AJCP7QHH5XASTJPL] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
307 Schuler MK, Kroschinsky F, Schaich M, Kalauch A, Stroszczynski C, Kellermann S, Ehninger G, Benter T. Sézary syndrome: infiltration of the gastric wall--does it matter? Ann Hematol. 2012;91:1507-1509. [PMID: 22362119 DOI: 10.1007/s00277-012-1426-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol. 2012;67:867-875. [PMID: 22285675 DOI: 10.1016/j.jaad.2011.12.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
309 Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, Shigematsu A, Endo T, Tanaka J, Hashino S, Tanaka S, Imamura M. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol 2012;95:217-22. [DOI: 10.1007/s12185-012-1003-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
310 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2012;1:CD008908. [PMID: 22258991 DOI: 10.1002/14651858.cd008908.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
311 Connor OO, Jain S, Zain J. Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics 2012. [DOI: 10.1007/978-94-007-5028-9_15] [Reference Citation Analysis]
312 Finn WG, Macon WR. Mature T-Cell and Natural Killer Cell Leukemias. Hematopathology 2012. [DOI: 10.1016/b978-1-4377-2606-0.00013-5] [Reference Citation Analysis]
313 Nazareth F, Victoria Quaresma M, Bernardes F, Gustavo Carneiro Castro C, Pellegrini Nahn E, Augusto da Costa Nery J, Carrijo Rochael M, Lupi O. Hypopigmented Mycosis Fungoides in a 7-Year-Old Boy. JCDSA 2012;02:64-67. [DOI: 10.4236/jcdsa.2012.22015] [Reference Citation Analysis]
314 Gulia A, Massone C. Primary cutaneous T-cell lymphomas. Journal of the Egyptian Womenʼs Dermatologic Society 2012;9:1-13. [DOI: 10.1097/01.ewx.0000407896.95730.63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
315 Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. Current Opinion in Oncology 2012;24:S1-S10. [DOI: 10.1097/01.cco.0000410158.56500.c4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
316 Hernández-barrera NR, Knobler R, Moncada B. Tratamiento de linfomas cutáneos de células T con fotoinmunoterapia extracorpórea (Fotoféresis). Piel 2011;26:523-531. [DOI: 10.1016/j.piel.2011.07.003] [Reference Citation Analysis]
317 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [PMID: 21990092 DOI: 10.1002/ajh.22139] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
318 Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R. Revisiting Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. International Journal of Radiation Oncology*Biology*Physics 2011;81:e651-7. [DOI: 10.1016/j.ijrobp.2011.01.023] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
319 Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis. Journal of Dermatological Science 2011;64:1-6. [DOI: 10.1016/j.jdermsci.2011.07.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
320 Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155:150-66. [PMID: 21883142 DOI: 10.1111/j.1365-2141.2011.08852.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
321 Velagapudi P, Turagam M, Uzoaru I, Graham D. Small bowel obstruction due to mycosis fungoides: an unusual presentation. Am J Med Sci. 2011;341:508-509. [PMID: 21613936 DOI: 10.1097/maj.0b013e31821389da] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
322 Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008;2:717-24. [PMID: 19707452 DOI: 10.2147/btt.s3084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
323 Raphael BA, Morrissey KA, Kim E, Vittorio CC, Rook A. Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2011;65:212-4. [DOI: 10.1016/j.jaad.2010.06.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
324 Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, Popplewell L, Gaal K, Senitzer D, Kogut N, O'Donnell M, Forman SJ. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 2011;52:1463-73. [PMID: 21699453 DOI: 10.3109/10428194.2011.574754] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
325 VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64:525-531. [PMID: 21587264 DOI: 10.1038/ja.2011.35] [Cited by in Crossref: 199] [Cited by in F6Publishing: 209] [Article Influence: 16.6] [Reference Citation Analysis]
326 Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598-2607. [PMID: 21576639 DOI: 10.1200/jco.2010.32.0630] [Cited by in Crossref: 428] [Cited by in F6Publishing: 445] [Article Influence: 35.7] [Reference Citation Analysis]
327 Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, Demierre MF. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol 2010;49:1393-8. [PMID: 21155090 DOI: 10.1111/j.1365-4632.2010.04567.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
328 Sánchez MA, González T, Gaitán MF, Zuluaga A, Jiménez SB, de Galvis YT. Is PUVA maintenance therapy necessary in patients with early-stage mycosis fungoides? Evaluation of a treatment guideline over a 28-month follow-up. Int J Dermatol 2011;50:1086-93. [PMID: 21375528 DOI: 10.1111/j.1365-4632.2010.04833.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
329 Booher S, Mccann SA, Tawa MC. Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Sézary Syndrome, Part 2. Journal of the Dermatology Nurses' Association 2011;3:75-83. [DOI: 10.1097/jdn.0b013e318211ff2e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
330 Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012;47:65-72. [PMID: 21358679 DOI: 10.1038/bmt.2011.16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
331 Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre M, Pittelkow M, Wilson LD, Pinter-brown L, Advani R, Parker S, Kim EJ, Junkins-hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology 2011;64:352-404. [DOI: 10.1016/j.jaad.2010.08.037] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 10.3] [Reference Citation Analysis]
332 Stutz N, Nihal M, Wood GS. Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma. Br J Dermatol 2011;164:814-21. [PMID: 21070201 DOI: 10.1111/j.1365-2133.2010.10128.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
333 Weberschock T, Rehberger P, Röllig C, Bunch C, Schmitt J, Bauer A, Weberschock T. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
334 Leboit PE. Mycosis Fungoides and Sézary Syndrome. Hematopathology 2011. [DOI: 10.1016/b978-0-7216-0040-6.00038-1] [Reference Citation Analysis]
335 Booher S, Mccann SA, Tawa MC. Cutaneous T-Cell Lymphoma. Journal of the Dermatology Nurses' Association 2011;3:18-32. [DOI: 10.1097/jdn.0b013e31820a3e82] [Reference Citation Analysis]
336 Zwischenberger BA, Pandya AG, Guitart J. Cutaneous T-cell Lymphoma. Cancer of the Skin 2011. [DOI: 10.1016/b978-1-4377-1788-4.00021-6] [Reference Citation Analysis]
337 Fujita A, Hamada T, Iwatsuki K. Clinical features of patients with cutaneous lymphomas from Okayama University Hospital. Skin Cancer 2011;26:191-196. [DOI: 10.5227/skincancer.26.191] [Reference Citation Analysis]
338 Duncan LM, Kumar S. Primary Cutaneous T-Cell Lymphomas. Hematopathology. Elsevier; 2011. pp. 617-28. [DOI: 10.1016/b978-0-7216-0040-6.00040-x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
339 Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63:975-83. [PMID: 20888065 DOI: 10.1016/j.jaad.2009.12.052] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
340 Poligone B, Lin J, Chung C. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid 2011;6:1-12. [PMID: 21468238 DOI: 10.2147/CE.S9084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
341 Brattseva EV, Rotanov SV, Bratseva EV, Rotanov SV. Current approaches to diagnostics of mycosis fungoides. Vestnik dermatologii i venerologii 2010;86:16-22. [DOI: 10.25208/vdv773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
342 Clark RA, Shackelton JB, Watanabe R, Calarese A, Yamanaka K, Campbell JJ, Teague JE, Kuo HP, Hijnen D, Kupper TS. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 2011;117:1966-76. [PMID: 21148332 DOI: 10.1182/blood-2010-05-287664] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
343 Querfeld C, Rosen ST. Mycosis fungoides and Sézary syndrome. Management of Hematologic Malignancies 2010. [DOI: 10.1017/cbo9780511781926.022] [Reference Citation Analysis]
344 Whittaker SJ, Demierre M, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, Mcculloch W, Kim YH. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JCO 2010;28:4485-91. [DOI: 10.1200/jco.2010.28.9066] [Cited by in Crossref: 481] [Cited by in F6Publishing: 500] [Article Influence: 37.0] [Reference Citation Analysis]
345 Fujita A, Hamada T, Iwatsuki K. Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. J Dermatol. 2011;38:524-530. [PMID: 21352297 DOI: 10.1111/j.1346-8138.2010.01049.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
346 Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-4739. [PMID: 20855822 DOI: 10.1200/jco.2009.27.7665] [Cited by in Crossref: 512] [Cited by in F6Publishing: 534] [Article Influence: 39.4] [Reference Citation Analysis]
347 Porcu P. A look at the National Comprehensive Cancer Network guidelines for cutaneous lymphomas. Clin Lymphoma Myeloma Leuk 2010;10 Suppl 2:S109-11. [PMID: 20826394 DOI: 10.3816/CLML.2010.s.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
348 Gahlot S, Khan MA, Rishi L, Majumdar S. Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 2010;80:1650-61. [PMID: 20804743 DOI: 10.1016/j.bcp.2010.08.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
349 Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin Selectively Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines and Patients’ PBMCs: Potential Role for STAT-3 and NF-κB Signaling. Journal of Investigative Dermatology 2010;130:2110-9. [DOI: 10.1038/jid.2010.86] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 5.7] [Reference Citation Analysis]
350 Lawrence H, Shao L, Horii KA. Hypopigmented macules and patches on the extremities of a teenager. Pediatr Dermatol 2010;27:197-8. [PMID: 20537074 DOI: 10.1111/j.1525-1470.2010.01118.x] [Reference Citation Analysis]
351 Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767-771. [PMID: 20484084 DOI: 10.1182/blood-2009-11-251926] [Cited by in Crossref: 348] [Cited by in F6Publishing: 360] [Article Influence: 26.8] [Reference Citation Analysis]
352 Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R, Maloney DG. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 2010;150:170-8. [PMID: 20507311 DOI: 10.1111/j.1365-2141.2010.08210.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 0.3] [Reference Citation Analysis]
353 Whittaker SJ. Cutaneous Lymphomas and Lymphocytic Infiltrates. Rook's Textbook of Dermatology 2010. [DOI: 10.1002/9781444317633.ch57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
354 Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-vilar A. Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma. JCO 2010;28:1870-7. [DOI: 10.1200/jco.2009.26.2386] [Cited by in Crossref: 170] [Cited by in F6Publishing: 175] [Article Influence: 13.1] [Reference Citation Analysis]
355 Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365-2372. [PMID: 20351328 DOI: 10.1200/jco.2009.25.8301] [Cited by in Crossref: 118] [Cited by in F6Publishing: 124] [Article Influence: 9.1] [Reference Citation Analysis]
356 Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010;16:2106-14. [PMID: 20233883 DOI: 10.1158/1078-0432.CCR-09-2879] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
357 Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res 2010;2:53-9. [PMID: 21188096 DOI: 10.2147/cmar.s5009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
358 Laharanne E, Oumouhou N, Bonnet F, Carlotti M, Gentil C, Chevret E, Jouary T, Longy M, Vergier B, Beylot-Barry M, Merlio JP. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol 2010;130:1707-18. [PMID: 20130593 DOI: 10.1038/jid.2010.8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 6.5] [Reference Citation Analysis]
359 Burg G, Kempf W, Dummer R, Urosevic-maiwald M. Cutaneous Lymphoma, Leukemia and Related Disorders. Skin Cancer - A World-Wide Perspective 2010. [DOI: 10.1007/978-3-642-05072-5_18] [Reference Citation Analysis]
360 Chandra P, Oyarzo MP, Jones D. Cutaneous T-cell Lymphomas. Neoplastic Hematopathology 2010. [DOI: 10.1007/978-1-60761-384-8_24] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
361 Strutton G. Cutaneous infiltrates – lymphomatous and leukemic. Weedon's Skin Pathology 2010. [DOI: 10.1016/b978-0-7020-3485-5.00042-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
362 Valencak J, Trautinger F, Raderer M, Chott A, Der-petrossian M, Ivancic-brandenberger E, Knobler R, Kurtaran A, Hoffmann M. Somatostatin receptor scintigraphy in primary cutaneous T- and B-cell lymphomas: 111In-pentetreotide scintigraphy in primary cutaneous lymphomas. Journal of the European Academy of Dermatology and Venereology 2010;24:13-7. [DOI: 10.1111/j.1468-3083.2009.03330.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
363 Hoppe RT, Advani R, Kim YH. Mycosis Fungoides. Leibel and Phillips Textbook of Radiation Oncology 2010. [DOI: 10.1016/b978-1-4160-5897-7.00064-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Suzuki S, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. Journal of Dermatological Science 2010;57:37-43. [DOI: 10.1016/j.jdermsci.2009.10.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
365 . 41 Cutaneous infiltrates – lymphomatous and leukemic. Weedon's Skin Pathology 2010. [DOI: 10.1016/b978-0-7020-3485-5.00082-6] [Reference Citation Analysis]
366 Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33:1860-1868. [PMID: 19898220 DOI: 10.1097/pas.0b013e3181bf677d] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
367 Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-rodriguez C, Geskin LJ. Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma 2009;9:412-6. [DOI: 10.3816/clm.2009.n.082] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
368 Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337-53. [DOI: 10.1182/blood-2009-07-202895] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 7.7] [Reference Citation Analysis]
369 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant 2009;15:982-90. [PMID: 19589488 DOI: 10.1016/j.bbmt.2009.04.017] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 6.4] [Reference Citation Analysis]
370 Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L. Low-Dose Gemcitabine Efficacious in Three Patients With Tumor-Stage Mycosis Fungoides. Clinical Lymphoma and Myeloma 2009;9:E21-4. [DOI: 10.3816/clm.2009.n.079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
371 Zic JA. Controversies in the management of the cutaneous T cell lymphomas. Dermatologic Therapy 2009;22:407-17. [DOI: 10.1111/j.1529-8019.2009.01257.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
372 Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010;130:362-70. [PMID: 19675575 DOI: 10.1038/jid.2009.247] [Cited by in Crossref: 211] [Cited by in F6Publishing: 223] [Article Influence: 15.1] [Reference Citation Analysis]
373 Abbott R, Whittaker S, Morris S, Russell-jones R, Hung T, Bashir S, Scarisbrick J. Bexarotene therapy for mycosis fungoides and Sézary syndrome. British Journal of Dermatology 2009;160:1299-307. [DOI: 10.1111/j.1365-2133.2009.09037.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 5.6] [Reference Citation Analysis]
374 Goujon E, Truc G, Pétrella T, Maingon P, Jeudy G, Collet E, Galliot C, Dalac-Rat S. [Total skin electron beam therapy for early-stage mycosis fungoides: immediate results and long-term follow-up in 68 patients]. Ann Dermatol Venereol 2009;136:249-55. [PMID: 19328307 DOI: 10.1016/j.annder.2008.11.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
375 Grange F. [Should early-stage mycosis fungoides be considered as cancer?]. Ann Dermatol Venereol 2009;136:238-40. [PMID: 19328305 DOI: 10.1016/j.annder.2009.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
376 Horst BA, Kasper R, LeBoit PE. CD4+, CD56+ mycosis fungoides: case report and review of the literature. Am J Dermatopathol. 2009;31:74-76. [PMID: 19155730 DOI: 10.1097/dad.0b013e31818ffbe8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
377 Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Current Opinion in Oncology 2009;21:131-7. [DOI: 10.1097/cco.0b013e3283253190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
378 Russell SR. The Development of Two Educational Manuals for Patients, Doctors, and Nurses Dealing With Cutaneous T-Cell Lymphoma. Journal of the Dermatology Nurses' Association 2009;1:147. [DOI: 10.1097/01.jdn.0000350429.00745.a5] [Reference Citation Analysis]
379 Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. International Journal of Dermatology 2009;48:243-52. [DOI: 10.1111/j.1365-4632.2009.03771.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
380 Hamada T. A 2008 nationwide survey on cutaneous lymphomas. Skin Cancer 2009;24:192-198. [DOI: 10.5227/skincancer.24.192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
381 Horwitz SM. Novel Therapies for Cutaneous T-Cell Lymphomas. Clinical Lymphoma and Myeloma 2008;8:S187-92. [DOI: 10.3816/clm.2008.s.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
382 Pai RK, Mullins FM, Kim YH, Kong CS. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. Cancer 2008;114:323-32. [PMID: 18798522 DOI: 10.1002/cncr.23793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
383 Kim EJ, Introcaso CE, Richardson SK, Rook AH. Cutaneous T-Cell Lymphoma. Clinical and Basic Immunodermatology. [DOI: 10.1007/978-1-84800-165-7_25] [Reference Citation Analysis]
384 van Doorn R, van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K, Knijnenburg J, Boer JM, Willemze R, Tensen CP. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009;113:127-36. [PMID: 18832135 DOI: 10.1182/blood-2008-04-153031] [Cited by in Crossref: 161] [Cited by in F6Publishing: 166] [Article Influence: 10.7] [Reference Citation Analysis]
385 Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am 2008;46:175-98, vii. [PMID: 18619375 DOI: 10.1016/j.rcl.2008.03.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
386 Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, McCormack C. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008;112:3082-7. [PMID: 18647960 DOI: 10.1182/blood-2008-05-154609] [Cited by in Crossref: 121] [Cited by in F6Publishing: 129] [Article Influence: 8.1] [Reference Citation Analysis]
387 Kamstrup MR, Specht L, Skovgaard GL, Gniadecki R. A Prospective, Open-Label Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. International Journal of Radiation Oncology*Biology*Physics 2008;71:1204-7. [DOI: 10.1016/j.ijrobp.2007.11.039] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
388 Introcaso CE, Leber B, Greene K, Ubriani R, Rook AH, Kim EJ. Stem cell transplantation in advanced cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2008;58:645-9. [DOI: 10.1016/j.jaad.2007.12.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
389 Introcaso CE, Micaily B, Richardson SK, Junkins-hopkins JM, Yoon JS, Kim EJ, Vittorio CC, Rook AH. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome. Journal of the American Academy of Dermatology 2008;58:592-5. [DOI: 10.1016/j.jaad.2007.12.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
390 Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371:945-957. [PMID: 18342689 DOI: 10.1016/s0140-6736(08)60420-1] [Cited by in Crossref: 189] [Cited by in F6Publishing: 203] [Article Influence: 12.6] [Reference Citation Analysis]
391 Evens AM, Querfeld C, Rosen ST. T-Cell Non-Hogdkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma. [DOI: 10.1007/978-0-387-29346-2_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
392 Fink-puches R, Cerroni L. Cutaneous T-cell lymphoma and emerging therapies. Drug Discovery Today: Disease Mechanisms 2008;5:e69-e79. [DOI: 10.1016/j.ddmec.2008.09.010] [Reference Citation Analysis]
393 Duvic M, Foss FM. Mycosis Fungoides: Pathophysiology and Emerging Therapies. Seminars in Oncology 2007;34:S21-8. [DOI: 10.1053/j.seminoncol.2007.11.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
394 Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Gonzalez M, Huerta-guzmán J. Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals 2007;22:836-40. [DOI: 10.1089/cbr.2007.0402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
395 McCann SA. Cutaneous T-cell lymphoma: overview and nursing perspectives. Nurs Clin North Am 2007;42:421-55, vi-vii. [PMID: 17825663 DOI: 10.1016/j.cnur.2007.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
396 Miller JD, Kirkland EB, Domingo DS, Scull H, Jekutis B, Dallas M, Cooper KD, Baron ED. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photoderm Photoimm Photomed 2007;23:163-71. [DOI: 10.1111/j.1600-0781.2007.00300.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
397 Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007;157:433-40. [DOI: 10.1111/j.1365-2133.2007.07975.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 6.8] [Reference Citation Analysis]
398 Assaf C, Gellrich S, Steinhoff M, Nashan D, Weiße F, Dippel E, Coors E, Stein A, Gollin P, Henke U, Adam-murati S, Koch A, Klemke C, Stadler R, Sterry W. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). JDDG 2007;5:662-8. [DOI: 10.1111/j.1610-0387.2007.06337.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 4.5] [Reference Citation Analysis]
399 Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, Kupper TS. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007;110:3015-27. [PMID: 17638852 DOI: 10.1182/blood-2006-12-061507] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 5.6] [Reference Citation Analysis]
400 Assaf C, Sanchez JA, Lukowsky A, Kölble K, Fischer T, Amerio P, Sterry W, Walden P. Absence of Microsatellite Instability and Lack of Evidence for Subclone Diversification in the Pathogenesis and Progression of Mycosis Fungoides. Journal of Investigative Dermatology 2007;127:1752-61. [DOI: 10.1038/sj.jid.5700793] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
401 Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115. [PMID: 17577020 DOI: 10.1200/jco.2006.10.2434] [Cited by in Crossref: 777] [Cited by in F6Publishing: 813] [Article Influence: 48.6] [Reference Citation Analysis]
402 Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722. [PMID: 17540844 DOI: 10.1182/blood-2007-03-055749] [Cited by in Crossref: 976] [Cited by in F6Publishing: 1027] [Article Influence: 61.0] [Reference Citation Analysis]
403 Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT; ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-484. [PMID: 17339420 DOI: 10.1182/blood-2006-10-054601] [Cited by in Crossref: 331] [Cited by in F6Publishing: 342] [Article Influence: 20.7] [Reference Citation Analysis]
404 Witkiewicz A, Raghunath P, Wasik A, Junkins-hopkins JM, Jones D, Zhang Q, Odum N, Wasik MA. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Human Pathology 2007;38:462-7. [DOI: 10.1016/j.humpath.2006.09.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
405 Kadin ME. Cutaneous T-Cell Lymphomas and Rare T-Cell Non-Hodgkin Lymphomas. Pediatric Lymphomas. [DOI: 10.1007/978-3-540-68753-5_10] [Reference Citation Analysis]
406 Tan ES, Tang MB, Tan SH. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore. Australas J Dermatol 2006;47:248-52. [PMID: 17034466 DOI: 10.1111/j.1440-0960.2006.00290.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
407 Roberge D, Muanza T, Blake G, Shustik C, Vuong T, Freeman C. Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides? Br J Dermatol 2007;156:57-61. [DOI: 10.1111/j.1365-2133.2006.07559.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
408 Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E. Mycosis fungoides associated with B-cell malignancies. Br J Dermatol. 2006;155:379-386. [PMID: 16882178 DOI: 10.1111/j.1365-2133.2006.07346.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
409 Dummer R, Hauschild A, Skalsky J, Burg G, Weichenthal M. Bexarotene and systemic disease progression in CTCL? Journal of the American Academy of Dermatology 2006;55:365-6. [DOI: 10.1016/j.jaad.2006.01.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
410 Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome. J Am Acad Dermatol 2005;53:428-34. [PMID: 16112348 DOI: 10.1016/j.jaad.2005.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
411 Pavlotsky F, Barzilai A, Kasem R, Shpiro D, Trau H. UVB in the management of early stage mycosis fungoides. J Eur Acad Dermatol Venerol 2006;20:565-72. [DOI: 10.1111/j.1468-3083.2006.01557.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
412 Hoppe RT, Kim YY, Advani R. Primary Cutaneous Lymphomas. The Lymphomas 2006. [DOI: 10.1016/b978-0-7216-0081-9.50029-7] [Reference Citation Analysis]
413 Grange F. Pronostic des lymphomes T cutanés primitifs. Annales de Dermatologie et de Vénéréologie 2005;132:13-20. [DOI: 10.1016/s0151-9638(05)79613-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
414 Abeni D, Frontani M, Sampogna F, Sera F, Bolli S, Corona R, Baliva G, Russo G. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 2005;153:324-30. [DOI: 10.1111/j.1365-2133.2005.06755.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
415 Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, Filosa G, Mozzicafreddo G, Giacchetti A, Brandozzi G, Cataldi I, Barulli S, Ranaldi R, Scortechini AR, Capretti R, Fabris G, Leoni P; (for the Marche Regional Multicentric Study Group of Cutaneous Lymphomas). Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005;75:136-45. [DOI: 10.1111/j.1600-0609.2005.00497.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 2.8] [Reference Citation Analysis]
416 Boztepe G, Sahin S, Ayhan M, Erkin G, Kolemen F. Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. Journal of the American Academy of Dermatology 2005;53:242-6. [DOI: 10.1016/j.jaad.2005.03.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
417 Klemke C, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 2005;153:118-24. [DOI: 10.1111/j.1365-2133.2005.06676.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
418 Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115:798-812. [PMID: 15841167 DOI: 10.1172/JCI24826] [Cited by in Crossref: 176] [Cited by in F6Publishing: 211] [Article Influence: 9.8] [Reference Citation Analysis]
419 Beylot-barry M, Parrens M, Delaunay M, Thiebault R, Vergier B, Demascarel A, Dubus P, Beylot C, Merlio JP. Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up. Br J Dermatol 2005;152:1378-9. [DOI: 10.1111/j.1365-2133.2005.06621.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
420 Lap-shing K, Kuen-kong L. Mycosis fungoides - a retrospective study of 40 cases in Hong Kong. Int J Dermatol 2005;44:215-20. [DOI: 10.1111/j.1365-4632.2004.02362.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
421 Assaf C, Hummel M, Zemlin M, Steinhoff M, Geilen CC, Stein H, Orfanos CE. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis. J Clin Pathol 2004;57:1325-8. [PMID: 15563677 DOI: 10.1136/jcp.2004.017160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
422 Montserrat E. Chronic lymphoid leukemias. Textbook of Malignant Haematology, Second Edition 2004. [DOI: 10.1201/b14440-34] [Reference Citation Analysis]
423 7. Cutaneous T-Cell Lymphoma 2004. [DOI: 10.1201/b14250-12] [Reference Citation Analysis]
424 Sezary Syndrome. Cutaneous T-Cell Lymphoma 2004. [DOI: 10.1201/b14250-5] [Reference Citation Analysis]
425 Assaf C, Hummel M, Steinhoff M, Geilen CC, Orawa H, Stein H, Orfanos CE. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood 2005;105:503-10. [PMID: 15459015 DOI: 10.1182/blood-2004-06-2220] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 3.5] [Reference Citation Analysis]
426 Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clinics in Dermatology 2004;22:197-208. [DOI: 10.1016/j.clindermatol.2003.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
427 Scarisbrick J, Whittaker S, Wotherspoon A, Rosenwald A, Ott G. Cutaneous lymphoma. Lymphoma: Pathology, Diagnosis and Treatment 2001. [DOI: 10.1017/cbo9780511663369.017] [Reference Citation Analysis]
428 Fang Y, Wang L, Zhao WL. [Long non-coding RNA and lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2017;38:997-1000. [PMID: 29224331 DOI: 10.3760/cma.j.issn.0253-2727.2017.11.023] [Reference Citation Analysis]